Haemonetics Corporation engages in the design, development, manufacture, and marketing of automated blood component collection devices and surgical blood salvage devices in the United States and internationally. It provides various plasma products, including PCS brand plasma collection equipment and consumables, plasma collection containers, and intravenous solutions, as well as information technology platforms for plasma customers to manage their donors, operations, and supply chain; and blood center products comprising multicomponent collection system brand apheresis equipment to collect specific blood components integrated from the donor, automated cell processor brand solution to automate the washing and freezing of red cell components in the lab, and filtration products. The company also offers various hospital products, such as TEG thrombelastograph hemostasis analyzer system that measures a patient's hemostasis or the ability to form and maintain blood clots; Cell Saver system for cardiovascular surgery procedures; OrthoPAT surgical blood salvage system for orthopedic procedures; cardioPAT system to open heart surgeries; and IMPACT Online Web-based software platform that monitors and measures improvements in a hospital's blood management practices, provides hospitals with a view of their blood management metrics, and helps monitor transfusion rates. In addition, it offers SafeTrace Tx and BloodTrack suite of solutions, as well as El Dorado Donor donation and blood unit management systems. The company markets and sells its products to commercial plasma collectors, blood collection groups and independent blood centers, hospitals and hospital service providers, and national health organizations through its direct sales force, as well as independent distributors. Haemonetics Corporation was founded in 1971 and is headquartered in Braintree, Massachusetts.